【摘要】：目的:應(yīng)用meta分析評估左炔諾孕酮宮內(nèi)緩釋系統(tǒng)與口服孕激素治療子宮內(nèi)膜增生不伴不典型性的臨床療效。方法:使用計算機(jī)在Pub Med數(shù)據(jù)庫、中國知網(wǎng)(CNKI)、萬方數(shù)據(jù)庫、維普數(shù)據(jù)庫(VIP)、CBMdisc(中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫)中檢索左炔諾孕酮宮內(nèi)緩釋系統(tǒng)與口服孕激素治療子宮內(nèi)膜增生不伴不典型性的隨機(jī)對照試驗相關(guān)文獻(xiàn),制定嚴(yán)格的納入標(biāo)準(zhǔn)及排除標(biāo)準(zhǔn),進(jìn)行文獻(xiàn)篩選,按Cochrane協(xié)作網(wǎng)偏倚風(fēng)險評價工具對入選文獻(xiàn)進(jìn)行質(zhì)量評估,提取有效數(shù)據(jù),同時應(yīng)用Cochrane協(xié)作網(wǎng)提供的Review Manager 5.3軟件對相關(guān)數(shù)據(jù)進(jìn)行Meta分析。結(jié)果:根據(jù)本研究的納入與排除標(biāo)準(zhǔn),最終納入文獻(xiàn)11篇,其中英文7篇,中文4篇。Meta分析結(jié)果顯示:LNG-IUS與口服孕激素治療子宮內(nèi)膜增生不伴不典型性對比,LNG-IUS具有顯著的治療療效(組織病理學(xué)反應(yīng)),治療后3個月(OR=2.53,95%CI:[1.56,4.12],P=0.0002,7,I~2=0%,n=484)、治療后6個月(OR=4.07,95%CI:[2.16,7.67],P0.0001,5,I~2=0%,n=433)、治療后12個月(OR=8.73,95%CI:[4.48,16.99],P0.00001,3,I~2=53%,n=304)、治療后24個月(OR=7.46,95%CI:[2.55,21.78],P=0.0002,1,n=104)組織病理學(xué)反應(yīng)具有統(tǒng)計學(xué)差異;亞組分析:LNG-IUS與口服孕激素對比,LNG-IUS對子宮內(nèi)膜單純性增生有顯著治療療效(OR=2.68,95%CI:[1.25,5.73],P=0.01,7,I~2=0%,n=340);LNG-IUS對子宮內(nèi)膜復(fù)雜性增生有顯著治療療效(OR=4.30,95%CI:[2.23,8.29],P0.0001,5,I~2=0%,n=339);LNG-IUS與口服孕激素對比,LNG-IUS組顯著降低子宮切除率(OR=0.27,95%CI:[0.16,0.45],P0.00001,3,I~2=0%,n=324)。LNG-IUS與口服孕激素對比,兩者治療后陰道不規(guī)則流血率無統(tǒng)計學(xué)差異(OR=2.23,95%CI:[0.50,9.89],P=0.29,4,I~2=79%,n=270)。結(jié)論:LNG-IUS與口服孕激素相比,LNG-IUS治療子宮內(nèi)膜增生不伴不典型性具有顯著療效,提高了子宮內(nèi)膜逆轉(zhuǎn)率,同時降低子宮切除率,LNG-IUS可作為治療子宮內(nèi)膜增生不伴不典型性的一種安全、有效、適合不同群體的治療方案。
[Abstract]:Objective: to evaluate the clinical efficacy of levonorgestrel intrauterine sustained release system and oral progesterone in the treatment of endometrial hyperplasia without atypical by meta analysis. Methods: using computer in Pub Med database, (CNKI), Wanfang database, (VIP), database CBMdisc (Chinese Biomedical Literature Database) was used to search the literature about levonorgestrel intrauterine sustained release system and oral progesterone in the treatment of endometrial hyperplasia without atypical randomized controlled trials, and to formulate strict inclusion criteria and exclusion criteria. According to the risk evaluation tool of Cochrane cooperation network bias, the quality of selected documents was evaluated, and valid data were extracted. At the same time, the relevant data were analyzed by Meta using Review Manager 5.3 software provided by Cochrane cooperation network. Results: according to the inclusion and exclusion criteria of this study, 11 articles were included, 7 of which were in English and Chinese, and 4 were in Chinese. The results of Meta analysis showed that LNG-IUS and oral progesterone were not associated with atypical endometrial hyperplasia. LNG-IUS showed significant curative effect (histopathological response), 3 months after treatment (OR=2.53,95%CI: [1.56n4.12], P0. 0002 + 7 Igna 2 + 484), 6 months after treatment (OR=4.07,95%CI: [2.16 鹵7.67]). P0. 0001 + 5 ~ (5) I ~ (2 +), 12 months after treatment (OR=8.73,95%CI: [4.48 鹵16.99], P 0.00001 ~ (3) I ~ (2 +), 24 months after treatment (OR=7.46,95%CI: [2. 55 鹵21. 78], P = 0. 00021, P = 0. 001, P = 0. 00021, P < 0. 001, P = 0. 00021). The histopathological responses were statistically different. Subgroup analysis: compared with oral progesterone, LNG-IUS had a significant therapeutic effect on endometrial simple hyperplasia (OR=2.68,95%CI: [1.25v 5.73], OR=2.68,95%CI: 0.01 ~ (7) I ~ (2 +) compared with oral progesterone (P ~ (0.01), LNG-IUS had a significant therapeutic effect on endometrial simple hyperplasia (OR=2.68,95%CI: [1.25 鹵5.73], P < 0.01). LNG-IUS was effective in the treatment of complex hyperplasia of endometrium (OR=4.30,95%CI: [2.238.29], P0.0001 / 5 ~ (2 +). Compared with oral progesterone, LNG-IUS significantly decreased the rate of hysterectomy in LNG-IUS group (OR=0.27,95%CI: [0.16 ~ 0.45], P0.00001 ~ (3 +) I ~ (2 +). LNG-IUS was compared with oral progesterone. There was no significant difference in the rate of irregular vaginal bleeding between the two groups after treatment (OR=2.23,95%CI: [0.50 鹵9.89, P = 0.29, n = 29, n = 79, n = 270). Conclusion: compared with oral progesterone, LNG-IUS has a significant effect on endometrial hyperplasia without atypical type, and increases the rate of endometrial reversal and reduces the rate of hysterectomy. LNG-IUS can be used as a safe, effective and suitable treatment for endometrial hyperplasia without atypical.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R711.74

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王茜;子宮內(nèi)膜增生誤診為葡萄胎一例[J];臨床超聲醫(yī)學(xué)雜志;2002年05期

2 Sherif L.S.;Totongy M.;Tawfeek M.;A.M. Badawy;朱曉明;;流式細(xì)胞DNA研究能否預(yù)測子宮內(nèi)膜增生的預(yù)后[J];世界核心醫(yī)學(xué)期刊文摘(婦產(chǎn)科學(xué)分冊);2006年02期

3 劉長香;;子宮內(nèi)膜增生的治療[J];中國現(xiàn)代醫(yī)藥雜志;2006年03期

4 Clark T.J.;Neelakantan D.;Gupta J.K. ;黨慧敏;;子宮內(nèi)膜增生的治療:對現(xiàn)行治療方法的評價[J];世界核心醫(yī)學(xué)期刊文摘(婦產(chǎn)科學(xué)分冊);2006年09期

5 程曉東,呂衛(wèi)國,謝幸;子宮內(nèi)膜增生的診斷與治療現(xiàn)狀[J];中華婦產(chǎn)科雜志;2001年08期

6 葛秦生;子宮內(nèi)膜增生[J];生殖醫(yī)學(xué)雜志;2003年05期

7 王言奎,解其貴,羅兵,姜玉珍,徐冰;雌激素受體亞型在子宮內(nèi)膜增生中的表達(dá)[J];中國婦產(chǎn)科臨床雜志;2005年02期

8 冒小燕;張玉泉;;子宮內(nèi)膜增生的治療進(jìn)展[J];國外醫(yī)學(xué).婦產(chǎn)科學(xué)分冊;2006年02期

9 李揚;溫永琴;陳麗麗;;子宮內(nèi)膜增生的病理學(xué)診斷研究進(jìn)展[J];中國處方藥;2009年03期

10 俞梅;甄t熑，

本文編號：2361419